Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-cel and Glofitamab in Relapsed/Refractory Large B Cell Lymphoma
NCT06213311Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, CAR-T Cells, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2024; status: recruiting.
02
Drugs
glofitamabaxicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06213311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213311.